Cost description of chemotherapy regimens for the treatment of metastatic pancreas cancer.
about
Dilemma of first line regimens in metastatic pancreatic adenocarcinomaRandomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic AdenocarcinomaA modified regimen of biweekly gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer is both tolerable and effective: a retrospective analysis.Comparison of treatment patterns and economic outcomes among metastatic pancreatic cancer patients initiated on nab-paclitaxel plus gemcitabine versus FOLFIRINOX.Current status on the place of FOLFIRINOX in metastatic pancreatic cancer and future directions.Comparison of treatment patterns, resource utilization, and cost of care in patients with metastatic pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine or FOLFIRINOX.
P2860
Cost description of chemotherapy regimens for the treatment of metastatic pancreas cancer.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Cost description of chemothera ...... of metastatic pancreas cancer.
@en
Cost description of chemothera ...... of metastatic pancreas cancer.
@nl
type
label
Cost description of chemothera ...... of metastatic pancreas cancer.
@en
Cost description of chemothera ...... of metastatic pancreas cancer.
@nl
prefLabel
Cost description of chemothera ...... of metastatic pancreas cancer.
@en
Cost description of chemothera ...... of metastatic pancreas cancer.
@nl
P2093
P2860
P1433
P1476
Cost description of chemotherapy regimens for the treatment of metastatic pancreas cancer
@en
P2093
Bassel F El-Rayes
Christopher R Flowers
Daniel A Goldstein
Kavya Krishna
Tanios Bekaii-Saab
P2860
P2888
P356
10.1007/S12032-016-0762-8
P577
2016-04-11T00:00:00Z